# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0002022626-25-000005
Filing Date
2025-09-02
Accepted
2025-09-02 08:38:15
Documents
13
Period of Report
2025-09-02
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | upb-20250902.htm iXBRL | 8-K | 56662
2 | EX-99.1 | upb-ex99_1.htm | EX-99.1 | 34182
3 | EX-99.2 | upb-ex99_2.htm | EX-99.2 | 1107
4 | PDF COURTESY COPY | upb-ex99_2.pdf | EX-99.2 | 1507802
| Complete submission text file | 0002022626-25-000005.txt |  | 2192157

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | upb-20250902.xsd | EX-101.SCH | 26961
15 | EXTRACTED XBRL INSTANCE DOCUMENT | upb-20250902_htm.xml | XML | 5106

Mailing Address 890 WINTER STREET, SUITE 200 WALTHAM MA 02451
Business Address 890 WINTER STREET, SUITE 200 WALTHAM MA 02451 781-208-2466
Upstream Bio, Inc. (Filer) CIK: 0002022626 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42366 | Film No.: 251283123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)